Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages
Internal Medicine Journal · 2025
DOI: 10.1111/imj.70074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Sara Shu-Ling Ng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, South Western Sydney Local Health District, Liverpool Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Intracranial Hemorrhages, Pyrazoles, Rivaroxaban. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
An increasing number of patients in Australia are taking direct oral anticoagulants for a variety of indications since their introduction in the treatment landscape. There has always been some concern about the optimal management approach in the setting of major and/or life‐threatening bleeding. In particular, patients who present with factor Xa inhibitor‐associated intracranial haemorrhages are associated with high morbidity and mortality.
Aim
To determine the efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐related intracranial haemorrhages.
Methods
A retrospective audit of rivaroxaban and apixaban‐associated intracranial haemorrhages was performed between January 2015 and December 2021, inclusive.
Results
The bleeding‐related mortality was similar between the patients who received pro‐haemostatic agents versus patients who did not receive pro‐haemostatic agents (90% vs 93% respectively). The mean volume expansion for those who received pro‐haemostatic agents was +1.0mL versus −6.8 mL for patients who did not receive pro‐haemostatic agents ( P = 0.51, 95% confidence interval: −11.7 to +5.9).
Conclusion
Patients who presented with intracranial haemorrhages in the presence of clinically significant direct oral anticoagulant levels had a higher risk of mortality that does not appear to change with the use of prohaemostatic agents. The efficacy of prohaemostatic agents may not be as clinically significant based on real‐world experience in contrast to previously reported studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology Department, South Western Sydney Local Health District, Liverpool Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, South West Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
- Radiology Department, South Western Sydney Local Health District, Liverpool Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Sara Shu-Ling Ng
Zitieren
APA
Ng, S. S., Noori, H., Nguyen, D., Wang, Z., & Hsu, D. (2025). Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages. Internal Medicine Journal. https://doi.org/10.1111/imj.70074
Vancouver
Ng SS, Noori H, Nguyen D, Wang Z, Hsu D. Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages. Internal Medicine Journal. 2025. doi:10.1111/imj.70074
BibTeX
@article{Ng2025,
author = {Ng, Sara Shu-Ling and Noori, Hashim and Nguyen, Diem and Wang, Zhengbang and Hsu, Danny},
title = {Efficacy of pro‐haemostatic agents in the management of factor Xa inhibitor‐associated intracranial haemorrhages},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.70074}
}
EUVIMED